Walgreens Chosen for Alzheimer's Trial Recruitment

Late-stage clinical biotechnology company Prothena has engaged Walgreens for its patient identification and recruitment of its ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. PRX012 has been granted Fast Track designation by the FDA.

Ramita Tandon, chief clinical trials officer, Walgreens said in a press release, “Through Walgreens trusted community pharmacy presence and daily interactions with millions of patients across America, we believe we can have a meaningful impact in helping Prothena with their clinical trial recruitment efforts. Our aim is to help build a more representative patient population for Alzheimer’s research, particularly among underserved and diverse communities, to create a better understanding of this disease.”

Using Walgreens pharmacy and patient-authorized clinical data, the company will identify and engage with potentially eligible patients and their caregivers to educate them on Prothena’s ASCENT-2 clinical trial. Walgreens will then invite interested patients or their caregivers to complete a pre-screen to determine eligibility for participation at one of Prothena’s clinical trial sites.

Prothena’s Phase I PRX012 single ascending dose (SAD) and multiple ascending dose (MAD) studies are ongoing with topline data expected year end 2023.

Reference: Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial. DEERFIELD, Ill. & DUBLIN--BUSINESS WIRE.